What the company actually pays, and whether its own cash supports it.
What stands out
Pays more per share than it earned over the last twelve months
Dividends view
Yield
1.76%
Annual Rate
CNY 0.18Paid unknown
Payout Ratio
200.0%High
Payback Period
44.6 yr
Last Ex-Dividend
Jun 8, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.31BCNY
646.56M · vs all stocks (USD)
Updated Oct 21, 2026
Trailing P/E
110.67x
vs Diagnostics & Research peers
Updated Oct 21, 2026
Revenue (TTM)
1.28BCNY
191.90M · vs all stocks (USD)
Updated Oct 21, 2026
Profit Margin
3.02%
vs Diagnostics & Research peers
Updated Oct 21, 2026
Beta
0.5230x
vs all stocks
Updated Oct 21, 2026
52-Week Change
13.25%
vs all stocks
Updated Oct 21, 2026
Forward Annual Dividend Yield
1.76%
vs all stocks
Updated Oct 21, 2026
Market Capitalization
4.31BCNY
646.56M · vs all stocks (USD)
Updated Oct 21, 2026
Enterprise Value
3.41BCNY
510.88M · vs all stocks (USD)
Updated Oct 21, 2026
Trailing P/E
110.67x
vs Diagnostics & Research peers
Updated Oct 21, 2026
Price to Sales (TTM)
3.12x
vs Diagnostics & Research peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 3.37×.Updated Oct 21, 2026
Price to Book (MRQ)
2.56x
vs Diagnostics & Research peers
Updated Oct 21, 2026
Enterprise to Revenue
2.66x
vs Diagnostics & Research peers
Updated Oct 21, 2026
Enterprise to EBITDA
23.81x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 29.23×.Updated Oct 21, 2026
Gross Margin
27.15%
vs Diagnostics & Research peers
Updated Oct 21, 2026
Profit Margin
3.02%
vs Diagnostics & Research peers
Updated Oct 21, 2026
Operating Margin
11.89%
vs Diagnostics & Research peers
Updated Oct 21, 2026
Return on Assets (TTM)
2.30%
vs Diagnostics & Research peers
Updated Oct 21, 2026
Return on Equity (TTM)
3.46%
vs Diagnostics & Research peers
Updated Oct 21, 2026
Revenue (TTM)
1.28BCNY
191.90M · vs all stocks (USD)
Updated Oct 21, 2026
Revenue per Share (TTM)
4.36CNYUpdated Oct 21, 2026
Quarterly Revenue Growth
-25.50%
vs Diagnostics & Research peers
Updated Oct 21, 2026
Gross Profit (TTM)
340.75MCNY
51.08M · vs all stocks (USD)
Updated Oct 21, 2026
EBITDA (TTM)
116.60MCNY
17.48M · vs all stocks (USD)
Updated Oct 21, 2026
Net Income (TTM)
38.63MCNY
5.79M · vs all stocks (USD)
Updated Oct 21, 2026
Quarterly Earnings Growth (YoY)
1061.20%
vs Diagnostics & Research peers
Updated Oct 21, 2026
Operating Cash Flow (TTM)
384.47MCNY
57.63M · vs all stocks (USD)
Updated Oct 21, 2026
Levered Free Cash Flow (TTM)
213.18MCNY
31.95M · vs all stocks (USD)
Updated Oct 21, 2026
Forward Annual Dividend Rate
0.1800CNYUpdated Oct 21, 2026
Forward Annual Dividend Yield
1.76%
vs all stocks
Updated Oct 21, 2026
Trailing Annual Dividend Rate
0.1800CNYUpdated Oct 21, 2026
Trailing Annual Dividend Yield
1.76%
vs all stocks
Updated Oct 21, 2026
Payout Ratio
200.00%
vs Diagnostics & Research peers
Updated Oct 21, 2026
Minority Interest (Equity)
96.35MCNYFY2025 · Dec 31, 2025
Revenue
1.45BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
1.10BCNYFY2025 · Dec 31, 2025
Gross Profit
346.98MCNYFY2025 · Dec 31, 2025
Operating Income
29.56MCNY
4.43M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
10.53MCNYFY2025 · Dec 31, 2025
Income Tax Expense
25.95MCNYFY2025 · Dec 31, 2025
Net Income
-15.42MCNYFY2025 · Dec 31, 2025
EBIT
16.95MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
116.60MCNYFY2025 · Dec 31, 2025
Research & Development
41.05MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
75.32MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
5.75MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
6.12MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
6.41MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.0800CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.0800CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
384.33MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
384.33MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-15.42MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-15.32MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
179.15MCNYFY2025 · Dec 31, 2025
Free Cash Flow
128.50MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
697.96MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-15.42MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
30.31MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
117.95MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
46.32MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-50.65MCNYFY2025 · Dec 31, 2025
Net Acquisitions
3.52MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-1.99BCNYFY2025 · Dec 31, 2025
Sale of Investments
1.91BCNYFY2025 · Dec 31, 2025
Other Investing Activity
6.45KCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-122.88MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
50.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-135.80MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-92.70MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-15.31MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-193.81MCNYFY2025 · Dec 31, 2025
Shares Outstanding
400.52MSharesUpdated Oct 21, 2026
Float Shares
165.17MSharesUpdated Oct 21, 2026
% Held by Insiders
59.74%
vs all stocks
Updated Oct 21, 2026
% Held by Institutions
1.49%
vs all stocks
Updated Oct 21, 2026
Total Cash (MRQ)
761.42MCNY
114.13M · vs all stocks (USD)
Updated Oct 21, 2026
Total Cash per Share (MRQ)
1.91CNYUpdated Oct 21, 2026
Total Debt (MRQ)
114.23MCNY
17.12M · vs all stocks (USD)
Updated Oct 21, 2026
Total Debt to Equity (MRQ)
0.0698x
vs Diagnostics & Research peers
Updated Oct 21, 2026
Current Ratio (MRQ)
4.04x
vs Diagnostics & Research peers
Updated Oct 21, 2026
Book Value per Share (MRQ)
3.89CNYUpdated Oct 21, 2026
Total Assets
2.29BCNY
343.58M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.75BCNYFY2025 · Dec 31, 2025
Total Liabilities
647.39MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
540.40MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
116.21MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
531.18MCNYFY2025 · Dec 31, 2025
Cash
759.44MCNYFY2025 · Dec 31, 2025
Cash Equivalents
58.99KCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
759.50MCNYFY2025 · Dec 31, 2025
Accounts Receivable
682.91MCNYFY2025 · Dec 31, 2025
Inventory
269.81MCNYFY2025 · Dec 31, 2025
Accounts Payable
402.62MCNYFY2025 · Dec 31, 2025
Short-term Debt
62.06MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
290.08KCNYFY2025 · Dec 31, 2025
Long-term Debt
109.38MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
120.00KCNYFY2025 · Dec 31, 2025
Common Stock (Book)
400.52MCNYFY2025 · Dec 31, 2025
Retained Earnings
530.33MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.64BCNY
246.54M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
23.01MCNYFY2025 · Dec 31, 2025
52-Week Low
7.86CNYUpdated Oct 21, 2026
52-Week High
14.55CNYUpdated Oct 21, 2026
52-Week Change
13.25%
vs all stocks
Updated Oct 21, 2026
Beta
0.5230x
vs all stocks
Updated Oct 21, 2026
50-Day MA
11.26CNYUpdated Oct 21, 2026
200-Day MA
10.35CNYUpdated Oct 21, 2026
Avg 10-Day Volume
15.95MSharesUpdated Oct 21, 2026
Avg 30-Day Volume
16.01MSharesUpdated Oct 21, 2026
Diluted EPS (TTM)
0.0900CNYUpdated Oct 21, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 2.00Dividend per Share: 0.18Earnings per Share: 0.09